rewirebio.iobenchmarks
Protocol

Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials

Split each held-out trial's patients at the method's median predicted risk and estimate the progression-free-survival hazard ratio of the higher-risk half against the lower-risk half, then take the geometric mean over three trials.

7 evaluations · 7 results

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

7 recorded evaluations, 7 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.

View coverage and remaining gaps across all benchmarks

Results

Results are available, but no reviewed comparison panel is linked in this release.

All evaluations

7 evaluations · 7 results. Different protocols are not a single leaderboard.

Protocol: Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials · Dataset subset: Three held-out trials with progression-free survival

Sorted by Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, progression-free survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over three trials) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

All 7 result rows with coverage, uncertainty and sources
Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: BulkFormer 147M (Ladon report comparator)Protocol: Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials
Dataset subset: Three held-out trials with progression-free survival
1.52 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, progression-free survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over three trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 3/3 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

BulkFormer, held-out trials PFS hazard ratio

ladon-20261115-protocol-trials-pfs-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'BulkFormer', label 'PFS 1.52'
Configuration: BulkRNABert, published Hugging Face checkpoint (Ladon report comparator)Protocol: Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials
Dataset subset: Three held-out trials with progression-free survival
1.6 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, progression-free survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over three trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 3/3 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

BulkRNABert, held-out trials PFS hazard ratio

ladon-20261115-protocol-trials-pfs-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'BulkRNABert', label 'PFS 1.60'
Configuration: Clinical covariates encoded by BMRetriever-7B (Ladon report baseline)Protocol: Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials
Dataset subset: Three held-out trials with progression-free survival
1.66 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, progression-free survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over three trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 2/3 trials scored (IMbrave150 has no patient-specific clinical covariates, so its clinical-only hazard ratio is not estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

Clinical covariates (BMRetriever), held-out trials PFS hazard ratio

ladon-20261115-protocol-trials-pfs-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'Clinical covariates (BMRetriever)', label 'PFS 1.66'
Method: Differential gene expression signature (Ladon report)Protocol: Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials
Dataset subset: Three held-out trials with progression-free survival
1.74 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, progression-free survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over three trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 3/3 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

Differential gene expression, held-out trials PFS hazard ratio

ladon-20261115-protocol-trials-pfs-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'Differential gene expression', label 'PFS 1.74'
Configuration: Ladon, survival mid-trained, ridge Cox fitted on TCGA and other trials (held-out trials)Protocol: Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials
Dataset subset: Three held-out trials with progression-free survival
1.9 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, progression-free survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over three trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 3/3 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

Ladon, held-out trials PFS hazard ratio

ladon-20261115-protocol-trials-pfs-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'Ladon', label 'PFS 1.90'
Configuration: Ladon + clinical covariates, summed standardised risk scores (held-out trials)Protocol: Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials
Dataset subset: Three held-out trials with progression-free survival
2 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, progression-free survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over three trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 3/3 trials scored (IMbrave150 uses Ladon alone in the combined predictor.)

Author-reported evaluation · Source checked
Methods, coverage and source

Ladon + clinical covariates, held-out trials PFS hazard ratio

ladon-20261115-protocol-trials-pfs-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'Ladon + clinical covariates', label 'PFS 2.00'
Method: Isoform TPM features (Ladon report)Protocol: Held-out trials, PFS hazard ratio of higher- against lower-risk half, geometric mean over three trials
Dataset subset: Three held-out trials with progression-free survival
1.33 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, progression-free survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over three trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 3/3 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

TPM · matched TCGA, held-out trials PFS hazard ratio

ladon-20261115-protocol-trials-pfs-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'TPM · matched TCGA', label 'PFS 1.33'

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Methods and evaluation design

Procedure, tasks and evaluated configurations

Recorded evaluations

Each evaluation records what was tested and under which conditions.

Baseline coverage

Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.

0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.

No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.

Author-reported evaluations
7

Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.

Null control

Proposed control: requires review

Select a task-valid null control after reviewing inputs and metric

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Conventional reference

Proposed control: requires review

Select an upstream conventional reference after reviewing the full protocol

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)

Coverage is derived from release 2026-11-21-c8bea25e5abb. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.

Run instructions

No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance

No evidence rows match these filters. Choose another scope or clear the search.

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID ladon-20261115-protocol-trials-pfs-hazard-ratio.

Source locator: Figure 3 (page 7) and caption; pages 13 and 14

Related records

Suggest a correction